Pizzie Nick 4

What Happened

• Pizzie Nick, Chief Financial Officer of Axsome Therapeutics (AXSM), received a grant of 18,570 restricted stock units (RSUs) on February 26, 2026. The grant is reported as a derivative award at $0.00 per unit (no cash purchase).
• RSUs represent a contingent right to receive one share of Axsome common stock per unit when vested; the filing does not state an immediate cash value or any sale/purchase of shares.

Key Details

• Transaction date: 2026-02-26; filing date: 2026-02-27 (Form 4 accession 0001193125-26-083608).
• Transaction type/code: Award/Grant (derivative) — reported as A.
• Units granted: 18,570 RSUs; price shown: $0.00 (typical for compensation awards).
• Vesting: 25% of the RSUs vest on the one-year anniversary of the grant; the remaining RSUs vest in three substantially equal annual installments, with the award fully vesting on February 26, 2030. Vested shares are deliverable upon the earlier of a Change in Control, the reporting person’s separation of service, or seven years from grant.
• Shares owned after transaction: not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or late filing notation is indicated in the reported details.

Context

• This is a compensation-related grant (an RSU award), not an open-market buy or sale. Such awards are common for executive compensation and vest over time, so they do not necessarily signal immediate insider buying or selling.
• Because RSUs convert into shares only upon vesting (or earlier qualifying events described above), they represent future potential ownership rather than an immediate change in share count available for trading.